Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30306223 | 1.00 | DRD2 (0.45) | DRD2DRD3CES2CES1NOTUM | |
| SCHEMBL30323255 | 0.81 | TSHR (0.44) | CES2CES1NOTUM | |
| SCHEMBL4018322 | 0.80 | KMT2A (0.44) | DRD2DRD3CES2CES1 | |
| SCHEMBL14231689 | 0.80 | KMT2A (0.44) | DRD2DRD3CES2CES1 | |
| SCHEMBL4020417 | 0.80 | NOS3 (0.43) | NOTUMPPARDNOS3AADAT | |
| SCHEMBL31278201 | 0.79 | MAPT (0.42) | NOTUMPPARDAADAT | |
| SCHEMBL14392644 | 0.79 | MAPT (0.42) | NOTUMPPARDAADAT | |
| SCHEMBL17887656 | 0.79 | DRD2 (0.49) | DRD2DRD3AADAT | |
| SCHEMBL3301244 | 0.79 | CYP1A2 (0.43) | PPARD | |
| SCHEMBL27269561 | 0.79 | SLC18A3 (0.38) | PPARDNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-10662199-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2701699-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-9890172-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20180016282-A9 | INHIBITORS OF HISTONE DEACETYLASE | HOWARD HUGHES MEDICAL INSTITUTE | 2018-01-18 | — | — | US | disclosed |
| US-20170217955-A9 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-20160347761-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2016-12-01 | — | — | US | disclosed |
| US-9447030-B2 | Inhibitors of histone deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160251351-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9365498-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| EP-2701699-A1 | INHIBITORS OF HISTONE DEACETYLASE | The Broad Institute, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149540-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE INC (US) | 2012-11-01 | — | — | WO | disclosed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | DRD2 1758/4885DRD3 1478/4885CES2 1503/4885 |
| US-20160347761-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC11 | DRD2 1758/4885DRD3 1478/4885CES2 1503/4885 |
| US-10662199-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | DRD2 1758/4885DRD3 1478/4885CES2 1503/4885 |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC11 | DRD2 1758/4885DRD3 1478/4885CES2 1503/4885 |
| US-11572368-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | DRD2 1758/4885DRD3 1478/4885CES2 1503/4885 |
| US-20160251351-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC11 | DRD2 2171/4885DRD3 1608/4885CES2 1577/4885 |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | DRD2 1758/4885DRD3 1478/4885CES2 1503/4885 |
| US-20170217955-A9 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC11 | DRD2 2171/4885DRD3 1608/4885CES2 1577/4885 |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | DRD2 801/4885DRD3 903/4885CES2 107/4885 |
| US-20180016282-A9 | INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC11 | DRD2 1758/4885DRD3 1478/4885CES2 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.